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Abstract
Background: Aberrant regulation in the invasion of cancer cells is closely associated with their metastatic
potentials. TrkB functions as a receptor tyrosine kinase and is considered to facilitate tumor metastasis. Pyk2 is a
non-receptor tyrosine kinase and integrates signals in cell invasion. However, little is known about the expression
of TrkB in NSCLC and whether Pyk2 is involved in TrkB-mediated invasion of A549 cells.
Methods: The expression of TrkB was investigated in NSCLC by immunohistochemical staining. Both HBE and
A549 cells were treated with BDNF. The expression of TrkB, Pyk2 and ERK phosphorylations were assessed by
western blot. Besides, A549 cells were transfected with TrkB-siRNA or Pyk2-siRNA, or treated with ERK inhibitor
where indicated. Transwell assay was performed to evaluate cell invasion.
Results: 40 cases (66.7%) of NSCLC were found higher expression of TrkB and patients with more TrkB expression
had significant metastatic lymph nodes (p = 0.028). BDNF facilitated the invasion of A549 cells and the activations
of Pyk2 in Tyr402 and ERK. However, the effects of BDNF were not observed in HBE cells with lower expression of
TrkB. In addition, the increased Pyk2 and ERK activities induced by BDNF were significantly inhibited by blocking
TrkB expression, so was the invasion of A549 cells. Knockdown studies revealed the essential role of Pyk2 for BDNF-
induced cell invasion, since the invasion of A549 cells was abolished by Pyk2-siRNA. The application of ERK
inhibitor also showed the suppressed ERK phosphorylation and cell invasion.
Conclusion: These data indicated that higher expression of TrkB in NSCLC was closely correlated with lymph node
metastasis, and BDNF probably via TrkB/Pyk2/ERK promoted the invasion of A549 cells.
Background
Lung cancer is the leading cause of death among the
malignant tumors worldwide, and the incidence of non-
small cell lung cancer (NSCLC) is increasing. The prog-
nosis of patients with NSCLC principally correlates with
tumor metastasis, which involves the regulation of some
critical genes and more information should be gathered
on the research of those prometastatic genes.
Tropomysin-related kinase B (TrkB) is a member of
Trk family, functions as a receptor tyrosine kinase.
Brain-derived neurotrophic factor (BDNF), the primary
ligand, binding to TrkB results in the regulation of var-
ious cellular activities in neuroblastoma, such as cell dif-
ferentiation [1], apoptosis [2], and invasion [3]. TrkB is
up-regulated in a variety of primary human tumors,
including neuroblastoma [4] and ovarian cancer [5],
especially in metastatic gastric [6] and pancreatic tumors
[7]. Enhanced TrkB signaling promotes cell survival in
an anchorage-independent manner [8]. When activated
by BDNF, TrkB leads to the activation of downstream
signaling molecules, such as phosphoinositide-3 kinase/
protein kinase B (PI3K/Akt) [9-11], which induces the
differential regulation of apoptosis and metastasis. How-
ever despite the increasing emphasis on TrkB in human
tumors, whether it positively participates in primary
human NSCLC has not yet been determined. At present,
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cit signalings downstream of TrkB in the progression of
NSCLC.
Proline-rich tyrosine kinase 2 (Pyk2) is an extensively
expressed non-receptor tyrosine kinase and integrates
signals from receptor tyrosine kinases and intracellular
signaling molecules in the essential cellular processes
such as cell differentiation [12], proliferation [13] and
migration [14]. Pyk2 is rapidly tyrosine phosphorylated
in response to various extracellular signals [15,16] and
activated Pyk2 signaling promotes cell survival and
migration in an anchorage-independent manner [17].
The tyrosine 402 (Tyr402) of Pyk2 serves as the primary
autophosphorylation site that is essential for Pyk2 activ-
ity and function [18], which is supported by the high
activity of Tyr402 found in tumor cells with a more
invasive and metastatic phenotype [19,20].
This study is designed to investigate the expression and
clinical significance of TrkB in 60 cases of surgically
resected NSCLC and the potential downstream signaling
of TrkB in BDNF-induced invasion of A549 cells. We
reported here that high expression of TrkB was common
in NSCLC, particularly correlated with lymph node metas-
tasis and TNM stage. We also reported that TrkB-siRNA
interrupted BDNF-promoted Pyk2 and extracellular regu-
lating kinase (ERK) activations and invasion of A549 cells.
Similarly, Pyk2-siRNA inhibited BDNF-associated ERK
phosphorylation and cells invasion. Therefore, TrkB/Pyk2/
ERK signaling was considered to mediate BDNF-induced
invasion of A549 cells. These results identify TrkB as a
potential novel regulator of cell invasion and the suppres-
sion of TrkB may provide a helpful target for inhibitory
therapies of metastasis in NSCLC.
Methods
NSCLC Samples
A total of 60 cases of NSCLC were obtained from the
Pathology Department of China Medical University.
This study was approved by the Medical Research Ethics
Committee of China Medical University and the
informed consent was obtained from all patients. All of
the enrolled patients underwent curative surgical resec-
tion without having chemotherapy or radiation therapy.
Formalin-fixed paraffin-embedded sections of tumor
were stained routinely with hematoxylin and eosin (HE),
and reviewed by two senior pathologists in order to
determine the histological type and stage, according to
the WHO classification of lung and pleural tumors
(2004) and the TNM staging system (1997). Lymph
node status was determined by routine pathological
examination of dissected nodes. Clinicopathological
information of the patients about tumor size, histologi-
cal type, differentiation, stage and lymph node metasta-
sis was obtained from patient records, and summarized
in Table 1.
Immunohistochemistry
60 paraffin sections of NSCLC were deparaffinized and
rehydrated routinely. The recovery of antigens was per-
formed by heating the slides in an autoclave sterilizer
for 2 min in 0.1 mol/L Tris-HCl at pH10. The sections
were incubated overnight at 4°C with primary rabbit
polyclonal antibody detecting TrkB (1:100 dilution,
Santa Cruz), following 3% H2O2 and 5% rabbit serum
treatment at 37°C for 1 h. After which they were incu-
bated with second antibody and streptavidin-peroxidase
(SP) complex for 30 min (SP kit, MaiXin, China), and
Table 1 Clinicopathological characteristics of 60 cases of NSCLC and TrkB expression by immunohistochemistry.
Clinicopathological charateristics Cases (n = 60) Higher exression (n = 40) Lower expression (n = 20) P value
Tumor size and invasiveness
T1+T2 40 27 13 0.846
T3+T4 20 13 7
Histological type
Sq 25 15 10 0.355
Ad 35 25 10
Differentiation
well-moderate 44 28 16 0.409
Poor 16 12 4
Stage
I+II 34 19 15 0.043*
III 26 21 5
Lymph node status
+ 30 24 6 0.028**
-3 0 1 6 1 4
TrkB expression: * = significant difference between early (I+II) and advanced (III) stage of NSCLCs; ** = significant difference between tumors with positive (+)
and negative (-) nodes.
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Page 2 of 8then visualized with 3,3’-diaminobenzidine (DAB). Neu-
roblastoma sections were used as positive controls for
TrkB, and negative controls were prepared by non-
immune rabbit IgG. All the immunoreactions were sepa-
rately evaluated by two senior pathologists. Cells with
brown particles appearing in cell membrane or cyto-
plasm was as regarded as TrkB-positive. The intensity of
TrkB immunostaining (1 = weak, 2 = intense) and the
percentage of positive tumor cells (0% = negative, 1-50%
= 1, 51-75% = 2, ≥ 76% = 3) were assessed in at least 5
high power fields (×400 magnification). The scores of
each tumorous sample were multiplied to give a final
s c o r eo f0 ,1 ,2 ,3 ,4 ,o r6 ,a n dt h et u m o r sw e r ef i n a l l y
determined as negative: score 0; lower expression: score
≤ 3; or higher expression: score > 3.
Cells culture and treatments
Human bronchial epithelial (HBE) and lung adenocarci-
noma A549 cells were preserved in our department.
HBE cells were grown in RPMI 1640 and A549 cells
were cultured in DMEM (Invitrogen) supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin
and streptomycin, in incubator with 5% CO2 at 37°C.
HBE and A549 cells (80-90% confluence) were firstly
treated with 100 ng/ml BDNF for 24 h. To knockdown
TrkB or Pyk2 for subsequent studies, A549 cells (50-
60% confluence) were transfected with either TrkB- or
Pyk2-siRNA and scrambled control siRNA (GeneChem,
China) for 48 h using Lipofectamin2000 (Invitrogen),
according to the manufacturer’s instructions. Cells were
then treated with 100 ng/ml BDNF at 24 h after trans-
fection and maintained for another 24 h. Where indi-
cated, the ERK inhibitor (PD98059, Calbiochem) at 100
μmol/L was added to cells for 48 h. Cells were also trea-
ted with 100 ng/ml BDNF at 24 h after PD98059 treat-
ment and maintained throughout the experiments.
Those cells treated were used for proteins extraction or
cell invasion analysis as described below. The experi-
ments for cells were repeated at least three times.
Cell invasion analysis
Cell invasion assay was performed using a 24-well
Transwell chamber (Costar). At 24 h following treat-
ments as described above, cells (1 × 10
4) were detached
and seeded in the upper chamber (containing 100 ng/ml
BDNF) with an 8 μm pore size insert precoated with
Matrigel (BD Biosciences) in the 24-well plate and cul-
tured for another 24 h. Cells were allowed to migrate
towards medium containing 15% FBS in the bottom
chamber. The non-migratory cells on the upper mem-
brane surface were removed with a cotton tip, and the
migratory cells attached to the lower membrane surface
were fixed with 4% paraformaldehyde and stained with
hematoxylin. The number of migrated cells was counted
in 5 randomly selected 200× power fields under micro-
scope. Data expressed are representative of three indivi-
dual wells.
Western blot
Cells were washed twice with ice-cold phosphate buffer
saline (PBS) and lysed in lysis buffer containing 20 mM
Tris-HCl, 1 mM EDTA, 50 mM NaCl, 50 mM NaF, 1
mM Na3VO4, 1% Triton-X100, 1 mM phenylmethyl sul-
fonylfluoride (PMSF) and phosphatase inhibitor. The
homogenate was centrifuged at 15000 rpm for 30 min
at 4°C. The supernatant was extracted and protein con-
tent was determined by the BCA (bicinchoninic acid)
assay (Pierce). 80 μg of total protein was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) and then transferred to polyvinylidene
fluoride (PVDF) membrane. After blocking with 5%
bovine serum albumin (BSA), primary antibodies includ-
ing rabbit polyclonal anti-TrkB, anti-Pyk2, anti-p-
Tyr402, anti-b-actin, mouse monoclonal anti-p-ERK (all
from Santa Cruz) were incubated on the membranes
overnight at 4°C. The membranes were then incubated
for 2 h at 37°C with secondary antibodies (ZhongShan,
China). Immunoreactive straps were identified using the
enhanced chemiluminescence (ECL) system (KeyGEN,
China), as directed by the manufacturer. The DNR Ima-
ging System was used to catch up the specific bands,
and the optical density of each band was measured
using the Image J software. The ratio between the opti-
cal density of interest proteins and b-actin of the same
sample was calculated as the relative content of protein
detected.
Statistical analysis
The SPSS 13.0 software was applied to complete data
processing. c
2-test was applied to analyze the correla-
tions between TrkB expression and clinicopathological
characteristics. T-test or One-way ANOVA was used to
compare the differences between cells with various
treatments. All data were represented as mean ± SD
and results were considered statistically significant when
the p-value was less than 0.05.
Results
The Expression of TrkB in 60 NSCLCs by
Immunohistochemistry
TrkB immunoreactivity was detected in 52 (86.7%) neo-
plastic sections. We considered that 40 (66.7%) cases of
NSCLC were higher expression (scores of 4 or 6) and
20 cases (33.3%) were lower expression (scores of 0, 1, 2
or 3), as described above in Materials and methods.
TrkB has been reported to facilitate tumor metastasis
[21,22], and the association between TrkB expression
and the presence of lymph node metastasis at the time
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Page 3 of 8of resection was analyzed statistically. TrkB immunos-
taining was stronger in NSCLCs with lymph node
metastasis compared with those node negative cases and
a statistically significant correlation between higher
TrkB expression and positive node was found (P =
0.028). In addition, patients with higher TrkB expression
had advanced stage of NSCLC (I+II versus III, P =
0.043). However, no significant difference of TrkB
expression was found between tumor size (T1+T2 ver-
sus T3+T4, P = 0.846), histological type (Ad versus Sq,
P = 0.355) and differentiation (well-moderate versus
poor, P = 0.409). Samples of TrkB expression in
NSCLCs with and without lymph node metastasis are
shown in Figure 1. The correlations of TrkB expression
and clinicopathological characteristics are shown in
Table 1.
Effect of BDNF on Cell Invasion
To investigate the potential signaling induced by BDNF
that regulates cell invasion, HBE and A549 cells were
used in this study. TrkB expression was examined in
HBE and A549 cells and simultaneously, the invasion of
these cells treated by BDNF was analyzed by Transwell
assay. A549 cells exhibited much higher level of TrkB,
which was hardly detectable in HBE cells (Figure 2A).
A ss h o w ni nF i g u r e2 C ,t h ei n v a s i v en u m b e r so fH B E
and A549 cells with or without BDNF treatment at 24 h
time point were 10.8 ± 1.4, 11.7 ± 1.9 (p = 0.549) and
19.5 ± 3.5, 30.7 ± 5.0 (P = 0.033), respectively. We also
examined the activations of Pyk2 and ERK after BDNF
treatments. Pyk2 phosphorylation in Tyr402 was
increased in A549 cells upon BDNF stimulation, which
was not observed in TrkB-null expressed HBE cells. The
activity of ERK was also elevated by BDNF in A549
cells, compared with HBE cells (Figure 2B). These
results showed that BDNF promoted the invasion of
TrkB-positive A549 cells probably via Pyk2 phosphoryla-
tion in Tyr402, and the activations of both Pyk2 and
ERK were participated in BDNF-induced invasion of
A549 cells.
Figure 1 The expression of TrkB in NSCLC examined by immunohistochemistry. TrkB immunostaining in lung squamous cell carcinoma
with (A) and without (B) lymph node metastasis. TrkB immunoreactivity in lung adenocarcinoma with (C) and without (D) positive nodes. It was
suggested that TrkB expression was correlated with lymph node status. Original magnification, all ×400.
Zhang et al. BMC Cancer 2010, 10:43
http://www.biomedcentral.com/1471-2407/10/43
Page 4 of 8Interruption of BDNF-induced Cell Invasion by TrkB-siRNA
To define the role of TrkB in regulating BDNF-stimu-
lated cell invasion, we utilized A549 cells due to the
high expression of TrkB and the facilities of culture and
transfection. The effects of decreased expression of
TrkB on BDNF-induced cell invasion and the activations
of Pyk2 and ERK by TrkB-siRNA were examined. Figure
3A showed that in TrkB-siRNA transfected A549 cells,
the inhibited TrkB led to the decreased activity of Pyk2
elicited by BDNF, which was detected by the phosphory-
lation of Tyr402, lower than that in non-silencing siRNA
transfected and control cells. The activation of ERK by
BDNF was also attenuated after TrkB blocking. The
invasive numbers of TrkB-siRNA, non-silencing and
control A549 cells were 32.7 ± 2.8, 30.7 ± 4.3 and 18.6
± 2.2 respectively (P = 0.003, Figure 3B). Therefore,
TrkB knockdown cells exhibited reduced Pyk2 and ERK
activations and diminished cell invasion.
Effect of Pyk2-siRNA on BDNF-induced Cell Invasion
Studies have shown that Pyk2 mediated cell invasion [23],
and we have observed the activation of Pyk2 by BDNF.
We next transiently established Pyk2 knockdown A549
cells by specific siRNA to determine the role of Pyk2 in
BDNF-induced cell invasion. Pyk2 knockdown cells had
TrkB expression similar to those non-silencing and con-
trol cells, as shown in Figure 4A. However the activation
of ERK by BDNF treatment was greatly reduced. In addi-
tion, the invasive numbers of Pyk2-siRNA, non-silencing
and control A549 cells were 29.4 ± 3.8, 30.0 ± 3.0 and 16.9
± 3.2, respectively (P = 0.005, Figure 4B). It seems that the
inhibited expression of Pyk2 in those cells significantly
correlated with decreased ERK activity and suppressed cell
invasion induced by BDNF.
Suppression of BDNF-induced Cell Invasion by PD98059
We further investigated whether the activated ERK was
definitely involved in BDNF promoted cell invasion by
treating A549 cells with PD98059, a specific inhibitor
for ERK. The inhibited phosphorylation of ERK was
available by PD98059, as Figure 5A demonstrated. The
invasive numbers of PD98059 treated or untreated A549
cells at 24 h were 27.9 ± 4.5 and 18.2 ± 3.6, respectively
(P = 0.042, Figure 5B). Consequently, in the presence of
PD98059, the activation of ERK was diminished concur-
rently with decreased invasive cells. It seems that the
activated ERK played an essential role in regulating the
invasion of A549 cells induced by BDNF. Collectively,
these data suggested a novel, functional role of BDNF
via TrkB in activating Pyk2 and ERK and enhancing the
invasion of A549 cells.
Discussion
T h ei n v a s i o no ft u m o rc e l l sp l a y sac r i t i c a lr o l ef o ra
successful metastasis. In this study, we investigated a
potential signaling that regulates the invasion of A549
cells. Our data suggested a novel signaling by which
BDNF facilitates the invasion of A549 cells via TrkB/
Pyk2/ERK pathway, which possibly contributes to the
metastasis of those lung cancer cells. Our study indi-
cated that TrkB plays a critical role in promoting the
invasion of A549 cells, which is mediated by a mechan-
ism closely associated with the activations of Pyk2 and
ERK.
Figure 2 Comparison of TrkB expression in HBE and A549 cells by western blot. HBE cells exhibited a minimal amount of TrkB and much
higher level of TrkB was found in A549 cells (A). In the presence of BDNF, the phosphorylations of Pyk2 in Tyr402 and ERK were promoted in
TrkB-positive A549 cells, which were not observed in TrkB-null HBE cells (A). Simultaneously, the invasive number of A549 cells was increased
after BDNF treatment, while the invasion of HBE cells was not affected (B). Original magnification, all ×400. The experiments for cells were
repeated at least three times.
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human tumors, such as hepatoma, pancreatic ductal
adenocarcinoma, Wilms’ tumor, astrocytoma and glio-
blastoma [24-27]. This study evaluated TrkB expression
to determine the clinical significance of TrkB for the
advanced NSCLC. We examined 60 cases of NSCLC by
means of immunohistochemistry and found a statistical
evidence of TrkB higher expression in NSCLC, and
patients with higher TrkB expression had a significant
metastatic phenotype, supporting the potential role of
TrkB in survival and metastasis of tumor cells [28,29].
Therefore, the higher expression of TrkB probably plays
an important role in the progression of NSCLC.
To investigate the potential function in BDNF-induced
cell invasion, TrkB expression was compared between
HBE and A549 cells. We found that the expression of
TrkB in HBE cells was much lower, and A549cells with
higher expression of TrkB seemed to be more invasive.
Thus, TrkB was considered to be involved in the inva-
sion of A549 cells. Compared with A549 cells, BDNF
had no effects on Pyk2 and ERK activations or the inva-
sion of HBE cells, which suggested that in TrkB-positive
A549 cells, up-regulated TrkB was readily activated
upon BDNF, and signaling pathways initiated by TrkB
led to an immediate activation of Pyk2 and Pyk2-
mediated functions.
Recent studies have been shown that inactivation of
Trk by tyrosine kinase inhibitors was correlated with the
inhibited invasion of tumor cells [30] and aiming at
interfering TrkB expression or activation might be help-
ful in the progression of effective anticancer therapies.
Our TrkB knockdown experiments in this study demon-
strated a critical role of TrkB in BDNF-induced Pyk2
and ERK activations and the invasion of A549 cells.
Further investigations shou l db ec a r r i e do u tf o rt h e
detailed activation and interaction between TrkB and
Pyk2 in other lung cancer cell lines or in vivo.
The involvement of Pyk2 in the invasion of TrkB-posi-
tive A549 cells was clearly evident that the phosphoryla-
tion in Tyr402 was up-regulated by BDNF as well as cell
invasion. Since BDNF-induced cell invasion was signifi-
cantly reduced in Pyk2 knockdown cells, it was indi-
cated that Pyk2 was required for regulating the invasion
of A549 cells. Pyk2-mediated functions were performed
by activating multiple downstream signaling molecules,
including ERK, p38, c-Src and paxillin, which led to the
Figure 3 Interruption of BDNF-induced cell invasion by TrkB-siRNA. In TrkB-siRNA transfected A549 cells, the decreased activity of Pyk2 in
Tyr402 promoted by BDNF was detected, which was much lower than that in non-silencing siRNA transfected and control cells. The activation
of ERK was also attenuated after TrkB silencing (A). The invasion of TrkB-siRNA transfected A549 cells was greatly inhibited, in comparison to
those non-silencing and control cells (B). Original magnification, all ×400. The data are representative of three individual experiments.
Figure 4 Effects of Pyk2-siRNA on BDNF-induced cell invasion. Pyk2 knockdown cells had TrkB expression unaffected, while the activation of
ERK promoted by BDNF treatment was largely reduced (A). In addition, the invasive number of Pyk2-siRNA transfected A549 cells was
significantly decreased and less than those non-silencing and control cells (B). Original magnification, all ×400. The data are representative of
three replicates.
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types [31-34]. The activation of ERK was observed after
BDNF treatment, which was inhibited by Pyk2-siRNA
and concomitant with a decreased cell invasion. Thus,
we considered that ERK activated by Pyk2 was partici-
pated in the invasion of A549 cells stimulated by BDNF.
Further experiments are necessary to clarify if other sig-
naling molecules are involved in BDNF-induced cell
invasion.
Taken together, our study confirmed that TrkB was
overexpressed in NSCLCs. When activated by BDNF,
TrkB induced Pyk2 phosphorylation in Tyr402, which
led to ERK activation and promoted cell invasion. Our
data thus revealed a TrkB/Pyk2/ERK signaling pathway
that regulated the invasion of A549 cells and provided
potential targets for the metastasis of NSCLC. Neverthe-
less, other signaling pathway(s) involved in the TrkB-
associated invasion of lung cancer cells required further
studies.
Conclusions
Our data suggested that TrkB was higher expressed in
NSCLC and patients with more TrkB expression had
significant metastatic lymph nodes. In A549 cells, when
activated by BDNF, TrkB mediated Pyk2 phosphoryla-
tion in Tyr402, led to ERK activation and promoted cell
invasion. Our data thus revealed the involvement of
TrkB in lymph node metastasis of NSCLC and a TrkB/
Pyk2/ERK signaling pathway that regulated the invasion
of A549 cells and provided potential targets for the
metastasis of NSCLC.
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